Skip to main content

Table 3 Plan parameters and significance of differences based on the pooled data of five patients and five institutes

From: Multi-institutional comparison of volumetric modulated arc therapy vs. intensity-modulated radiation therapy for head-and-neck cancer: a planning study

  

VMAT average ± 1 SD*

IMRT average ± 1 SD*

Average difference ± 1 SD* (VMAT – IMRT)

p-value (Wilcoxon’s signed-rank test)^

PTVboost

CI95

1.37 ± 0.08

1.45 ± 0.11

-0.08 ± 0.09

.001

PTVtotal

CI95

1.50 ± 0.09

1.62 ± 0.10

-0.12 ± 0.07

< .001

Normal tissue

V5Gy (cm3)

5050 ± 730

5030 ± 750

-20 ± 260

n.s.

V10Gy (cm3)

4050 ± 630

3970 ± 590

-80 ± 160

n.s.

V20Gy (cm3)

2830 ± 510

2860 ± 480

30 ± 150

n.s.

Spinal cord

Dmax (Gy)

45.1 ± 3.5

46.6 ± 3.0

-1.5 ± 2.3

.001

D1% (Gy)

43.4 ± 3.7

44.4 ± 3.5

-0.9 ± 2.2

.005

Dmean (Gy)

29.3 ± 4.4

29.8 ± 3.6

-0.5 ± 2.4

n.s.

Brain stem

Dmax (Gy)

46.4 ± 5.4

47.1 ± 4.7

-0.7 ± 4.6

n.s.

D1% (Gy)

43.8 ± 5.8

44.0 ± 5.5

-0.2 ± 4.9

n.s.

Dmean (Gy)

13.6 ± 3.6

14.5 ± 4.3

-1.0 ± 2.4

n.s.

Parotid gland ipsilateral

V25Gy (%)

42.9 ± 15.6

50.3 ± 20.0

-7.4 ± 14.0

< .001

V39Gy (%)

30.0 ± 14.6

35.9 ± 18.6

-5.9 ± 11.2

< .001

Dmean (Gy)

28.0 ± 7.5

31.1 ± 9.1

-3.1 ± 5.1

< .001

Parotid gland contralateral

V25Gy (%)

31.0 ± 7.1

34.5 ± 6.8

-3.5 ± 3.6

< .001

V39Gy (%)

18.3 ± 6.0

20.8 ± 6.1

-2.5 ± 2.5

< .001

Dmean (Gy)

22.0 ± 2.9

23.3 ± 2.8

-1.3 ± 1.5

< .001

Submandibular gland contralateral$

V39Gy (%)

88.1 ± 15.3

90.8 ± 13.5

-2.7 ± 6.9

n.s.

V60Gy (%)

16.4 ± 21.4

21.8 ± 27.3

-5.5 ± 8.5

.020

Dmean (Gy)

53.0 ± 5.9

54.2 ± 6.1

-1.3 ± 1.8

.027

Oral cavity

V25Gy (%)

79.8 ± 22.9

86.3 ± 15.7

-6.5 ± 10.2

.011

V39Gy (%)

40.6 ± 22.0

48.8 ± 23.3

-8.2 ± 12.4

.002

Dmean (Gy)

36.7 ± 7.8

39.4 ± 7.3

-2.7 ± 2.8

< .001

Larynx

V39Gy (%)

75.4 ± 24.7

79.1 ± 21.6

-3.8 ± 6.7

.012

V45Gy (%)

54.1 ± 27.4

58.2 ± 26.5

-4.1 ± 9.3

n.s.

Dmean (Gy)

45.5 ± 5.3

46.5 ± 4.4

-1.0 ± 1.5

.004

Pharyngeal constrictors°

V39Gy (%)

78.7 ± 24.5

81.5 ± 20.0

-2.8 ± 15.2

n.s.

V45Gy (%)

59.7 ± 29.4

57.5 ± 25.5

2.2 ± 19.9

n.s.

Dmean (Gy)

47.1 ± 5.3

46.9 ± 3.8

0.2 ± 2.7

n.s.

Mandible°

V39Gy (%)

74.0 ± 13.1

78.2 ± 11.8

-4.2 ± 8.4

.025

V60Gy (%)

25.7 ± 15.0

30.1 ± 16.2

-4.4 ± 5.1

< .001

Dmean (Gy)

48.6 ± 5.5

50.3 ± 5.7

-1.7 ± 1.7

< .001

Effective delivery time#

(min:sec)

5:54 ± 1:05

13:15 ± 1:38

-7:21 ± 1:55

< .001

MUs

--

643 ± 111

828 ± 149

-185 ± 129

< .001

  1. * Standard deviations (SDs) are given as absolute values.
  2. ^ Hypothesis testing using a paired t-test results in almost identical significances at 95% confidence level.
  3. $ The contralateral submandibular gland was delineated in only three patients.
  4. ° Not all institutes used objectives to control dose for these structures.
  5. # Based on effective delivery times reported by four institutes.